The present invention relates to pharmaceutical compositions comprising 4-pregenen-11β-17-21-triol-3,20-dione derivatives, and their use as pharmaceuticals as modulators of the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR). The invention relates specifically to the use of these compounds and their pharmaceutical compositions to treat ocular conditions associated with the glucocorticoid receptors (GR) and/or the mineralocorticoid receptors (MR).本發明係關於包含4-孕-11β-17-21-三醇-3,20-二酮衍生物之醫藥組合物及其作為醫藥之用途,該等醫藥為糖皮質激素受體(GR)及/或礦物皮質激素受體(MR)之調節劑。本發明特定言之係關於此等化合物及其醫藥組合物治療與糖皮質激素受體(GR)及/或礦物皮質激素受體(MR)相關之眼部病狀之用途。
